📣 VC round data is live. Check it out!
- Public Comps
- Biosynex
Biosynex Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biosynex and similar public comparables like ViroGates, Observe Medical, Advanced Medical, Scandinavian Real Heart and more.
Biosynex Overview
About Biosynex
Biosynex SA is engaged in the research, development, and manufacturing of fast diagnosis tests on membrane support for health professionals. It manufactures and markets medical devices for screening, diagnosis.
Founded
2005
HQ

Employees
128
Website
Financials (FY)
EV
$77M
Valuation Multiples
Start free trialBiosynex Financials
Biosynex reported last fiscal year revenue of $119M and negative EBITDA of ($22K).
In the same fiscal year, Biosynex generated $67M in gross profit, ($22K) in EBITDA losses, and had net loss of ($51M).
Biosynex P&L
In the most recent fiscal year, Biosynex reported revenue of $119M and EBITDA of ($22K).
Biosynex is unprofitable as of last fiscal year, with gross margin of 57%, EBITDA margin of (0%), and net margin of (43%).
Financial data powered by Morningstar, Inc.
Biosynex Stock Performance
Biosynex has current market cap of $16M, and enterprise value of $77M.
Market Cap Evolution
Biosynex's stock price is $0.86.
Biosynex share price decreased by 8.9% in the last 30 days, and by 42.5% in the last year.
Biosynex has an EPS (earnings per share) of $-2.75.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $77M | $16M | -5.4% | -8.9% | -21.7% | -42.5% | $-2.75 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiosynex Valuation Multiples
Biosynex trades at 0.7x EV/Revenue multiple, and (3465.7x) EV/EBITDA.
Biosynex Financial Valuation Multiples
As of May 8, 2026, Biosynex has market cap of $16M and EV of $77M.
Biosynex has a P/E ratio of (0.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biosynex Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Biosynex Margins & Growth Rates
In the most recent fiscal year, Biosynex reported gross margin of 57%, EBITDA margin of (0%), and net margin of (43%).
Biosynex Margins
Biosynex Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Biosynex Operational KPIs
Biosynex's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.9M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Biosynex Competitors
Biosynex competitors include ViroGates, Observe Medical, Advanced Medical, Scandinavian Real Heart, Labo Euromedis, Geratherm Medical, Boule Diagnostics, Diagnos, Bionano Genomics and Predilife.
Most Biosynex public comparables operate across Medical Devices, Medical Imaging & Diagnostics, HealthTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 8.8x | — | (7.5x) | — | |||
| 8.7x | — | (5.4x) | — | |||
| 61414.9x | — | 3626.1x | — | |||
| — | — | (4.1x) | — | |||
| 0.2x | — | 6.4x | — | |||
| 0.4x | — | 2.5x | — | |||
| 0.7x | 0.7x | 7.7x | 8.8x | |||
| 215.3x | — | (6.3x) | — | |||
This data is available for Pro users. Sign up to see all Biosynex competitors and their valuation data. Start Free Trial | ||||||
Biosynex M&A Activity
Biosynex has acquired 6 companies to date.
Last acquisition by Biosynex was on June 13th 2023. Biosynex acquired ProciseDx for undisclosed valuation.
Latest Acquisitions by Biosynex
| Description | ProciseDx is a diagnostics company specializing in point-of-care testing devices for rapid, accurate results. The platform delivers quantitative assays for biomarkers in minutes, enabling immediate clinical decisions without lab delays. Focused on infectious diseases and cardiac markers, ProciseDx devices integrate microfluidics and immunoassay technology. Based in Rockville, Maryland, it partners with healthcare providers to streamline patient workflows in clinics and emergency settings. | PARA’KITO is a Paris-headquartered company specializing in natural insect repellent technology. The firm manufactures wearable devices like bracelets and patches using a plant-based active ingredient effective against mosquitoes transmitting dengue, Zika, and malaria. PARA’KITO products are distributed in over 40 countries through pharmacies and retailers such as Boots and Walgreens, with clinical studies confirming up to eight hours of protection. | Avalun creates the Labpad, a portable in vitro diagnostic device yielding rapid test results from tiny sample volumes. | SR2B SA is a biotechnology firm developing reagents for microbiology and parasitology. Through http://www.sr2b.fr/, it produces parasitic antigens, fungal diagnostics, monoclonal antibodies, and lyophilized bioproducts with microparticle coupling for research labs in Europe. | |
| HQ Country | |||||
| HQ City | San Diego, CA | Fort Lauderdale, FL | Grenoble | Angers | |
| Deal Date | 13 Jun 2023 | 20 Apr 2022 | 3 May 2021 | 7 Jul 2017 | |
| Valuation | undisclosed | undisclosed | $12M | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Biosynex acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biosynex
| When was Biosynex founded? | Biosynex was founded in 2005. |
| Where is Biosynex headquartered? | Biosynex is headquartered in France. |
| How many employees does Biosynex have? | As of today, Biosynex has over 128 employees. |
| Is Biosynex publicly listed? | Yes, Biosynex is a public company listed on Euronext Paris. |
| What is the stock symbol of Biosynex? | Biosynex trades under ALBIO ticker. |
| When did Biosynex go public? | Biosynex went public in 2011. |
| Who are competitors of Biosynex? | Biosynex main competitors include ViroGates, Observe Medical, Advanced Medical, Scandinavian Real Heart, Labo Euromedis, Geratherm Medical, Boule Diagnostics, Diagnos, Bionano Genomics, Predilife. |
| What is the current market cap of Biosynex? | Biosynex's current market cap is $16M. |
| What is the current revenue of Biosynex? | Biosynex's last fiscal year revenue is $119M. |
| What is the current EV/Revenue multiple of Biosynex? | Current revenue multiple of Biosynex is 0.7x. |
| Is Biosynex profitable? | No, Biosynex is not profitable. |
| How many companies Biosynex has acquired to date? | As of May 2026, Biosynex has acquired 6 companies. |
| What was the largest acquisition by Biosynex? | $12M acquisition of Avalun on 3rd May 2021 was the largest M&A Biosynex has done to date. |
| What companies Biosynex acquired? | Biosynex acquired Avalun, Fumouze Diagnostics, SR2B SA, Dectra Pharm, ProciseDx, and PARA’KITO. |
| In how many companies Biosynex has invested to date? | Biosynex hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Biosynex
Lists including Biosynex
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

